India, April 8 -- Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. The company reported 67 percent overall response rate in target population, while the targeted response was 20 percent.
Currently, shares are at 1.11, up 7.41 percent on a volume of 937,099.
The trial reported 8.9 months median overall survival in Patients with AML-Myelodysplasia-Related Changes and 8.8 months median overall survival in all relapsed or refractory to Venetoclax-based regimens patients. The company said the results surpassed historical benchmark of ...